Asterand plc (ATD.L) said it has extended its collaboration with Bristol-Myers Squibb Co. (BMY) for access to Asterand's products and services for up to 3 years. The company noted that the agreement will focus on access to Asterand's PhaseZERO drug discovery services and Asterand's XpressBANKTM of human tissue and clinical samples for the continued validation of early drug targets and support for compound optimisation.
Under the extended collaboration, Asterand said it will continue to undertake a range of PhaseZERO studies for Bristol-Myers Squibb in the areas of compound profiling and target validation. PhaseZERO studies include gene and protein expression profiling and cell-based pharmacology assays.
Likewise, the company also stated that Bristol-Myers Squibb will be granted access to its XpressBANKTM of human tissue, bio-fluid, and cell lines and may also utilize Asterand's ProCURETM custom clinical sample collection service.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.